<DOC>
	<DOC>NCT00132652</DOC>
	<brief_summary>This study is being conducted to compare the safety and effectiveness of switching treatment from lamivudine to telbivudine (LdT) against continued lamivudine treatment. Results from patients who were taking lamivudine and then switched to telbivudine will be compared with the results from patients who continued on lamivudine alone.</brief_summary>
	<brief_title>Switching Therapy From Lamivudine to Telbivudine Versus Continued Lamivudine in Adults With Chronic Hepatitis B</brief_title>
	<detailed_description />
	<mesh_term>Hepatitis</mesh_term>
	<mesh_term>Hepatitis A</mesh_term>
	<mesh_term>Hepatitis, Chronic</mesh_term>
	<mesh_term>Hepatitis B</mesh_term>
	<mesh_term>Hepatitis B, Chronic</mesh_term>
	<mesh_term>Telbivudine</mesh_term>
	<mesh_term>Lamivudine</mesh_term>
	<criteria>Documented clinical history compatible with chronic hepatitis B Patient has compensated liver disease Patient has received previous treatment with lamivudine for a duration of at least 3 months and not more than 12 months Other protocoldefined inclusion criteria may apply. Patient is pregnant or breastfeeding Patient is coinfected with hepatitis C, hepatitis D or HIV Patient previously received antiviral treatment for hepatitis B other than lamivudine in the preceding 12 months Other protocoldefined exclusion criteria may apply.</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>70 Years</maximum_age>
	<verification_date>February 2017</verification_date>
</DOC>